Clinical Trial Update: Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) [Phase 2]

View source ↗

Summary

This is a Phase 2 safety evaluation of combining ibritumomab tiuxetan (Zevalin) with a fludarabine-based reduced-intensity conditioning regimen in patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Fludarabine (Fludarabine)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED